OverviewSuggest Edit

BioCryst is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. 
BioCryst's core development programs include BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema; and BCX4430 (GALIDESIVIR), a broad spectrum antiviral for hemorrhagic fevers.

TypePublic
Founded1986
HQDurham, NC, US
Websitebiocryst.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Jan 2020)140(+40%)
Job Openings36
Revenue (FY, 2020)$17.8 M(-63%)
Share Price (Nov 2021)$12.3
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BioCryst Pharmaceuticals

Robert A. Ingram

Robert A. Ingram

Chairman of the Board
Stephanie Angelini

Stephanie Angelini

Senior Vice President, Human Resources
Alane Barnes

Alane Barnes

Senior Vice President, Chief Legal Officer
Yarlagadda S. Babu

Yarlagadda S. Babu

Senior Vice President, Drug Discovery
Elliott Berger

Elliott Berger

Senior Vice President, Regulatory Affairs
Anthony Doyle

Anthony Doyle

Senior Vice President, Chief Financial Officer
Show more

BioCryst Pharmaceuticals Office Locations

BioCryst Pharmaceuticals has offices in Durham and Hoover
Durham, NC, US (HQ)
4505 Emperor Blvd #200
Hoover, AL, US
2100 Riverchase Center #200
Show all (2)

BioCryst Pharmaceuticals Financials and Metrics

BioCryst Pharmaceuticals Revenue

BioCryst Pharmaceuticals's revenue was reported to be $17.81 m in FY, 2020
USD

Revenue (Q1, 2021)

19.1m

Gross profit (Q1, 2021)

13.1m

Gross profit margin (Q1, 2021), %

68.9%

Net income (Q1, 2021)

(64.3m)

EBIT (Q1, 2021)

(51.4m)

Market capitalization (12-Nov-2021)

2.2b

Closing stock price (12-Nov-2021)

12.3

Cash (31-Mar-2021)

226.9m

EV

2.2b
BioCryst Pharmaceuticals's current market capitalization is $2.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

19.6m26.3m17.3m13.6m48.3m26.4m25.2m20.7m48.8m17.8m

Cost of goods sold

1.0k1.4m2.3m1.1m3.7m1.6m

Gross profit

13.6m46.9m24.1m24.0m45.1m16.3m

Gross profit Margin, %

100%97%91%95%92%91%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

3.7m5.2m12.2m4.2m5.8m3.6m2.4m3.5m1.5m3.2m6.8m25.8m11.0m4.8m4.8m7.8m9.4m3.1m8.8m4.0m12.5m1.5m5.9m1.4m1.8m4.8m2.9m6.1m19.1m

Cost of goods sold

15.0k1.3m1.1m1.4m1.5m5.9m

Gross profit

6.8m9.6m7.6m4.5m2.9m4.6m13.1m

Gross profit Margin, %

100%88%87%76%100%75%69%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

16.4m20.9m21.2m54.5m28.9m22.1m50.3m26.7m114.2m272.1m

Accounts Receivable

5.8m4.6m2.1m6.2m6.1m4.3m22.1m8.6m

Prepaid Expenses

378.0k1.1m1.7m6.2m4.9m1.4m2.4m4.4m5.5m

Inventories

263.0k4.0m683.0k1.6m500.0k1.6m7.0m
USDQ2, 2011

Debt/Equity

0.8 x

Debt/Assets

0.3 x

Financial Leverage

2.8 x
Show all financial metrics

BioCryst Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

BioCryst Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

BioCryst Pharmaceuticals Online and Social Media Presence

Embed Graph

BioCryst Pharmaceuticals News and Updates

Thinking about buying stock in Innoviz Technologies, Avaya Holdings, BioCryst Pharmaceuticals, Lithium Americas Corp, or FuelCell Energy?

NEW YORK, Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INVZ, AVYA, BCRX, LAC, and FCEL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Nokia, BioCryst Pharmaceuticals, Beam Therapeutics, Altimmune, or Citius Pharmaceuticals?

NEW YORK, April 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, BCRX, BEAM, ALT, and CTXR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Sundial Growers, RLX Technology, AMC Entertainment, BioCryst Pharmaceuticals, or GigCapital3?

NEW YORK, March 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, RLX, AMC, BCRX, and GIK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about trading options or stock in Rambus, Intellia Therapeutics, BioCryst Pharmaceuticals, Arcturus Therapeutics, or FuelCell Energy?

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMBS, NTLA, BCRX, ARCT, and FCEL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about buying stock in Sorrento Therapeutics, FAT Brands, BioCryst Pharmaceuticals, TOP Ships, or Tesla?

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, FAT, BCRX, TOPS, and TSLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating

DUBLIN, Sept. 25, 2018 /PRNewswire/ -- The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022. The report...
Show more

BioCryst Pharmaceuticals Blogs

BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones

BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones Content Import Wed, 11/03/2021 - 07:00 BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones November 3, 2021 at 7:00 AM EDT This release is a backfil…

Amy McKee, MD

Amy McKee, MD jennifer.segal… Mon, 09/20/2021 - 08:08 Member of the Science Amy McKee, MD Amy McKee, MD, was appointed to the Board in September 2021. Dr. McKee currently serves as vice president of regulatory consulting services for Parexel, a leading global clinical research org…

NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) has recommended ORLADEYO ® (berotralstat) for preventing recurrent attacks of

Steven Galson, MD, MPH

Steven Galson, MD, MPH Paul.alfano@na… Wed, 09/01/2021 - 11:04 Member of the Science Steven Galson, MD, MPH

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO ® (berotralstat) has been accepted for review by Health Canada for the prevention of recurrent attacks in patients with hereditary

BioCryst Withdraws Public Offering

BioCryst Withdraws Public Offering Content Import Tue, 08/10/2021 - 18:55 BioCryst Withdraws Public Offering August 10, 2021 at 6:55 PM EDT This release is a backfill from a News Wire General News General …
Show more

BioCryst Pharmaceuticals Frequently Asked Questions

  • When was BioCryst Pharmaceuticals founded?

    BioCryst Pharmaceuticals was founded in 1986.

  • Who are BioCryst Pharmaceuticals key executives?

    BioCryst Pharmaceuticals's key executives are Robert A. Ingram, Stephanie Angelini and Alane Barnes.

  • How many employees does BioCryst Pharmaceuticals have?

    BioCryst Pharmaceuticals has 140 employees.

  • What is BioCryst Pharmaceuticals revenue?

    Latest BioCryst Pharmaceuticals annual revenue is $17.8 m.

  • What is BioCryst Pharmaceuticals revenue per employee?

    Latest BioCryst Pharmaceuticals revenue per employee is $127.2 k.

  • Who are BioCryst Pharmaceuticals competitors?

    Competitors of BioCryst Pharmaceuticals include Cellarity, Boston Analytical and Origene Technologies.

  • Where is BioCryst Pharmaceuticals headquarters?

    BioCryst Pharmaceuticals headquarters is located at 4505 Emperor Blvd #200, Durham.

  • Where are BioCryst Pharmaceuticals offices?

    BioCryst Pharmaceuticals has offices in Durham and Hoover.

  • How many offices does BioCryst Pharmaceuticals have?

    BioCryst Pharmaceuticals has 2 offices.